Insider Selling: Athira Pharma, Inc. (NASDAQ:ATHA) CEO Sells $14,059.92 in Stock

Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton sold 25,107 shares of Athira Pharma stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $0.56, for a total transaction of $14,059.92. Following the sale, the chief executive officer now directly owns 242,591 shares in the company, valued at $135,850.96. The trade was a 9.38 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Athira Pharma Price Performance

NASDAQ:ATHA opened at $0.57 on Monday. Athira Pharma, Inc. has a 1-year low of $0.41 and a 1-year high of $4.30. The company has a market capitalization of $22.16 million, a PE ratio of -0.20 and a beta of 2.99. The firm’s 50-day moving average price is $0.61 and its 200-day moving average price is $1.49.

Athira Pharma (NASDAQ:ATHA) last released its earnings results on Thursday, November 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.05. Equities analysts anticipate that Athira Pharma, Inc. will post -2.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Mizuho cut Athira Pharma from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $5.00 to $0.50 in a research report on Thursday, September 19th.

Institutional Investors Weigh In On Athira Pharma

A number of institutional investors have recently modified their holdings of ATHA. Rothschild Investment LLC bought a new stake in Athira Pharma during the 2nd quarter valued at about $34,000. XTX Topco Ltd bought a new stake in shares of Athira Pharma during the second quarter valued at approximately $60,000. Invst LLC purchased a new position in Athira Pharma in the 2nd quarter worth approximately $68,000. American Century Companies Inc. lifted its position in Athira Pharma by 9.4% in the 2nd quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock valued at $103,000 after acquiring an additional 3,333 shares in the last quarter. Finally, Forefront Analytics LLC boosted its stake in Athira Pharma by 126.0% during the 2nd quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock valued at $123,000 after purchasing an additional 25,979 shares during the last quarter. 57.12% of the stock is owned by hedge funds and other institutional investors.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.